Key Insights• The India biosurgery market represents one of the fastest-growing national markets for surgical biomaterials globally, driven by the country's vast population, expanding healthcare infrastructure, and rapidly increasing surgical volumes. The market encompasses a broad range of biologically derived and bio-compatible materials including hemostatic agents, surgical sealants and adhesives, bone-graft substitutes, adhesion barriers, soft-tissue attachments, and staple-line reinforcement products that assist in surgical procedures by controlling bleeding, sealing tissues, promoting regeneration, and preventing postoperative complications.• The India biosurgery market is distinguished by its immense scale, with the country performing an estimated 3 crore (30 million) surgeries annually, with approximately 82% of procedures performed in small and medium hospitals. General surgery and obstetrics and gynecology have emerged as the dominant specialties. Healthcare expenditure in India stands at approximately 3.61% of GDP in 2025, with public healthcare spending at approximately 1.3-1.9% of GDP. The market is shaped by a complex interplay of demographic trends, technological innovation, regulatory frameworks, and evolving healthcare delivery models, including the rapid expansion of medical tourism, government initiatives promoting domestic manufacturing, and the increasing adoption of advanced surgical techniques.• Bone-Graft Substitutes represent the largest product category within the Indian biosurgery market, driven by the high volume of orthopedic and trauma procedures. India's rapidly growing population and rising road traffic accidents continue to drive demand for musculoskeletal interventions.Surgical Sealants and Adhesives represent the fastest-growing product category, driven by increasing adoption of minimally invasive surgical techniques and the expansion of medical tourism.

India's medical devices industry is projected to reach USD 50.1 billion by 2030, registering a CAGR of 26.9%.• India's aging population represents a significant long-term demand driver. As of 2025, the elderly population (65 and older) stands at approximately 7% of the population, with over 107.98 million people aged 65 or older, a figure that is expected to rise in the coming decades as life expectancy improves. The regulatory environment, centered on the Central Drugs Standard Control Organization (CDSCO) and the Medical Devices Rules, 2017, continues to transition towards a more structured, risk-based and digitised regulatory framework.Market Outlook• According to the research report, "India Biosurgery Market Overview, 2031 “published by Actual Market Research, the India Biosurgery market is anticipated to grow at more than 8.64% CAGR from 2026 to 2031.• The aging Indian population represents a significant long-term demand driver. As of 2025, the elderly population (65 and older) stands at approximately 7% of the population, with over 107.98 million people aged 65 or older, a figure that is expected to rise in the coming decades as life expectancy improves. India's population is estimated to reach 1.46 billion in 2025.• Technological innovation in biomaterials and surgical delivery systems is expanding the addressable market. India's medical devices industry is one of the fastest-growing segments in the healthcare sector.

The government's National Medical Devices Policy, 2023, aims to facilitate growth of the medical device sector through regulatory streamlining, enabling infrastructure, and facilitating research and development.• Rising surgical procedures and expanding healthcare access are key drivers propelling market expansion. India performs an estimated 3 crore (30 million) surgeries annually. The country also recorded 20,138 organ transplants in 2025, the highest-ever in a single year, highlighting the expanding surgical capacity. C-sections now account for over 27% of all reported childbirths in 2024-25.Market DynamicsDriver: Massive and Growing Surgical Volumes Across All SpecialtiesIndia performs tens of millions of surgical procedures annually across its vast network of hospitals and healthcare facilities. The country performs an estimated 3 crore (30 million) surgeries annually, with approximately 82% of procedures performed in small and medium hospitals. General surgery and obstetrics and gynecology have emerged as the dominant specialties.

C-sections now account for over 27% of all reported childbirths in 2024-25, representing a more than fourfold increase from 2008-09. India also recorded 20,138 organ transplants in 2025, the highest-ever in a single year, and now ranks third globally in the total number of organ transplants after the United States and China. The breadth and depth of surgical activity in India ensure that biosurgical products particularly hemostatic agents and sealants are utilized in virtually every operating room. The continued expansion of surgical capacity, driven by hospital modernization and the growing network of healthcare facilities, further reinforces this demand driver.Challenge: Healthcare Spending Constraints and Infrastructure GapsDespite the market's enormous size and growth potential, India faces significant challenges that limit the full potential of the biosurgery market. Healthcare expenditure in India stands at approximately 3.61% of GDP in 2025, with public healthcare spending at approximately 1.3-1.9% of GDP far below developed nations that spend upwards of 8-10%. Hospital bed density in India is approximately 1.5 beds per 1,000 population, lower than the global average of 2.9 and below 4 beds per 1,000 in countries like Germany and Japan.

Additionally, India faces a significant shortage of surgical workforce, requiring approximately 291,824 additional surgeons, obstetricians, and anaesthetists by 2030 to meet demand. These financial and operational constraints create pricing pressure on biosurgical products and may limit adoption of premium-priced advanced biologics in the public healthcare sector.Trend: Accelerating Domestic Manufacturing and Regulatory ModernizationThe Indian biosurgery market is experiencing a significant transformation driven by government policies promoting domestic manufacturing and regulatory modernization. The National Medical Devices Policy, 2023, approved by the Union Cabinet, aims to facilitate growth of the medical device sector, reduce import dependence, and establish India as a global manufacturing hub for medical devices. The policy aims to increase India's global market share from 1.6% to approximately 10-12% over the next 25 years. The Production Linked Incentive (PLI) Scheme for Promoting Domestic Manufacturing of Medical Devices continues to drive domestic production. The Medicines and Medical Devices (Price Control and Accessibility) Act, 2025 was enacted to regulate the prices of all medicines and medical devices, including implants and medical equipment.

In 2025, the CDSCO launched a new online Risk Classification Module for medical devices, simplifying regulatory approvals.Policies• The Central Drugs Standard Control Organization (CDSCO) serves as the primary regulatory authority for medical devices in India. In 2025, the CDSCO continued to implement the Medical Devices Rules, 2017, and released a draft list amending risk-based categorization for cardiovascular and neurological medical devices.• The National Medical Devices Policy, 2023, approved by the Union Cabinet, aims to facilitate growth of the medical device sector through regulatory streamlining, enabling infrastructure, and facilitating research and development and innovation.• The Medical Devices Rules, 2017 continues to serve as the regulatory framework for medical devices in India, with licensing compulsory for import, manufacture, sale, and distribution. The rules are transitioning towards a more structured, risk-based and digitised framework.• The Production Linked Incentive (PLI) Scheme for Medical Devices promotes domestic manufacturing of medical devices, with the government targeting to raise India's global market share from 1.6% to around 12% in the coming years.• The Medicines and Medical Devices (Price Control and Accessibility) Act, 2025 was enacted to establish an Authority to regulate the prices of all medicines and medical devices, including implants and medical equipment.• Ayushman Bharat - Pradhan Mantri Jan Arogya Yojana (AB-PMJAY) continues to expand healthcare access, with over 15,733 private hospitals empanelled under the scheme as of December 2025. A total of 177,906 Ayushman Arogya Mandirs have been established and operationalized as of 30th June 2025.Segment AnalysisIndia Biosurgery Market By Product• Bone-Graft Substitutes represent the largest product category within the Indian biosurgery market, driven by the high volume of orthopedic and trauma procedures. India's rapidly growing population, rising road traffic accidents, and increasing incidence of degenerative bone diseases continue to drive demand for musculoskeletal interventions. These products include demineralized bone matrix (DBM), synthetic bone grafts, and biologic grafts incorporating growth factors, widely utilized in trauma fixation, spinal fusion, and joint replacement procedures.• Hemostatic Agents constitute a major market segment, reflecting their essential role across all surgical disciplines.

These products including topical hemostats, flowable matrices, fibrin sealants, and thrombin-based agents are utilized in virtually every surgical procedure to control intraoperative bleeding. With India performing an estimated 3 crore (30 million) surgeries annually, demand for hemostatic products is substantial and growing.• Surgical Sealants and Adhesives represent the fastest-growing product category in the Indian biosurgery market, driven by increasing adoption of minimally invasive surgical techniques and the expansion of medical tourism. These products including fibrin sealants, synthetic polymer-based sealants, and protein-based adhesives are used to seal tissue surfaces, prevent fluid and air leaks, and reinforce surgical anastomoses. The growth of robotic and laparoscopic surgeries in India's private healthcare sector supports the expansion of this segment.• Adhesion Barriers represent a clinically important product category used to prevent postoperative adhesion formation in abdominal, pelvic, and gynecological surgeries. With C-sections now accounting for over 27% of all reported childbirths in India, the category continues to benefit from the high volume of gynecological and abdominal procedures.• Soft-Tissue Attachments encompass products used to reinforce, repair, or secure soft tissues, including surgical meshes, biologic scaffolds, and tissue grafts. These products are utilized in hernia repair, pelvic floor reconstruction, and various other soft-tissue procedures supported by high procedure volumes in Indian hospitals.• Staple-Line Reinforcement products are utilized in gastrointestinal, bariatric, and thoracic procedures to strengthen tissue interfaces along surgical staple lines, reducing the risk of bleeding and leakage.

The increasing volume of thoracic and gastrointestinal procedures supports steady demand for these products.India Biosurgery Market By Application• Orthopedic Surgery is the largest application area for biosurgical products in India, driven by the high volume of trauma surgeries, joint replacements, and spinal procedures. India's rapidly growing population, high incidence of road traffic accidents, and increasing burden of degenerative bone diseases continue to drive demand for musculoskeletal interventions. The aging population with over 107.98 million people aged 65 or older further supports growth in this specialty.• General Surgery encompasses a broad range of abdominal, gastrointestinal, and soft-tissue procedures, including bariatric surgery, colorectal surgery, and hernia repair. General surgery has emerged as the dominant specialty in India, with biosurgical products including hemostatic agents, surgical sealants, staple-line reinforcement products, and adhesion barriers utilized across these procedures.• Cardiovascular Surgery represents the fastest-growing application area in the Indian biosurgery market, driven by the high prevalence of cardiovascular disease. In 2025, 25.6% of surveyed individuals reported cardiovascular ailments, a significant increase from 16.7% recorded during 2017-18. Cardiovascular diseases have emerged as the leading cause of death among both men and women, with India accounting for one-fifth of global CVD-related deaths.

Vascular sealants, hemostatic agents, and soft-tissue attachments are increasingly utilized in cardiac and vascular procedures.• Neurological Surgery utilizes biosurgical products particularly hemostatic agents and dural sealants to manage bleeding and prevent cerebrospinal fluid leaks in cranial and spinal procedures. The aging population and increasing incidence of neurological conditions drive demand in this specialty.• Reconstructive Surgery involves the use of biosurgical products to restore, repair, or reconstruct damaged or surgically altered tissues, including soft-tissue repair, tissue reinforcement, and wound reconstruction following injury, disease, or surgery.• Gynecological Surgery includes biosurgical applications in procedures involving the female reproductive system, with products used for hemostasis, tissue sealing, adhesion prevention, tissue repair, and reinforcement. C-sections now account for over 27% of all reported childbirths in India, representing a more than fourfold increase from 2008-09.• Urological Surgery covers biosurgical applications in procedures involving the urinary tract and male reproductive system, with products used for bleeding control, tissue sealing, reinforcement, repair, and prevention of postoperative complications.• Thoracic and Other Surgeries represent a growing application area, driven by increasing adoption of video-assisted thoracoscopic surgery (VATS) and the rising burden of lung cancer and other thoracic conditions.India Biosurgery Market By Source/Origin• Biologic products represent the largest source category in the Indian biosurgery market, driven by their superior biocompatibility and natural healing properties. These products include demineralized bone matrix, fibrin sealants, collagen hemostats, allografts, and xenografts. The CDSCO's regulatory framework ensures safety standards for biological materials.• Synthetic and Semi-Synthetic products represent the fastest-growing source category in the Indian market, driven by cost-effectiveness, consistent quality, lower immunogenicity risks, and longer shelf life. These products include synthetic bone substitutes, PEG-based sealants, synthetic meshes, and polysaccharide hemostats.

The government's focus on domestic manufacturing and cost-effective healthcare solutions favors synthetic alternatives for certain applications.India Biosurgery Market By End-User• Hospitals remain the largest end-user segment for biosurgical products in India, accounting for the majority of revenue. With an estimated 3 crore (30 million) surgeries performed annually, hospitals are the primary setting for biosurgical product utilization. India has higher hospital density (4.5 for India vs 3.5 for rest of world) but lower bed density (1 bed per 1K population for India vs 2.7 for world). Over 15,733 private hospitals are empanelled under Ayushman Bharat - Pradhan Mantri Jan Arogya Yojana, while 468 hospitals were empanelled under CGHS in 2025.• Ambulatory Surgical Centers (ASCs) represent the fastest-growing end-user segment in the Indian biosurgery market, driven by the broader healthcare industry shift toward outpatient and same-day discharge models. The expansion of outpatient surgical capacity, supported by both public and private healthcare sectors, supports the adoption of biosurgical products in these settings.• Clinics represent a growing end-user segment, with specialty clinics performing eligible surgical or minimally invasive procedures utilizing biosurgical products for tissue repair, bleeding control, and sealing.India Biosurgery Market Economics• The Indian biosurgery market operates within a rapidly expanding healthcare system shaped by government investment, price controls, evolving procurement, and increasing domestic manufacturing. Healthcare expenditure stands at approximately 3.61% of GDP in 2025, while public healthcare spending is around 1.3–1.9% of GDP.

The Medicines and Medical Devices (Price Control and Accessibility) Act, 2025 and NPPA oversight create significant pricing pressure, including restrictions on annual price increases. Government tenders through CGHS, AB-PMJAY, and state programs remain important procurement channels, while hospital contracts and surgeon preferences influence private-sector demand.• India’s healthcare infrastructure is expanding across hospitals, specialty centers, clinics, and primary-care facilities. By June 2025, 177,906 Ayushman Arogya Mandirs had been operationalized, while more than 15,733 private hospitals were empanelled under AB-PMJAY. Although India has relatively high hospital density at 4.5 hospitals per population unit compared with 3.5 globally, bed density remains low at approximately one bed per 1,000 people versus 2.7 globally. The surgical workforce includes approximately 1.386 million registered allopathic doctors, but shortages remain substantial, with an estimated 291,824 additional surgeons, obstetricians, and anaesthetists required by 2030.• Domestic manufacturing and innovation are major growth priorities, supported by the Production Linked Incentive (PLI) Scheme and the National Medical Devices Policy, 2023. India’s medical devices industry is projected to expand from USD 15.2 billion in 2025 to USD 50.1 billion by 2030, while medical-device exports reached USD 4.1 billion in FY2025.

The regulatory framework, led by CDSCO and the Medical Devices Rules, 2017, is becoming increasingly risk-based and digitalized, including the 2025 online Risk Classification Module. Investment is also supported by growing adoption of robotic surgery, minimally invasive techniques, advanced biomaterials, and medical tourism.• Long-term biosurgery growth is supported by India’s large and aging population, with more than 107.98 million people aged 65 and above, alongside continued expansion of healthcare capacity and surgical technology. India’s medical tourism sector is also strengthening, with NRI customer share reportedly increasing 150% in FY2024–25 compared with the previous year. The India biosurgery market is anticipated to grow at more than 8.64% CAGR from 2026 to 2031, positioning the country among the fastest-growing markets globally. Manufacturers that localize production, manage price-control requirements, and align with government procurement and innovation priorities can capture significant opportunities.Considered in this report• Historic Year: 2020• Base year: 2025• Estimated year: 2026• Forecast year: 2031Aspects covered in this report• Biosurgery Market with its value and forecast along with its segments• Various drivers and challenges• On-going trends and developments• Top profiled companies• Strategic recommendationBy Product• Bone-Graft Substitutes• Hemostatic Agents• Surgical Sealants & Adhesives• Adhesion Barriers• Soft-Tissue Attachments• Staple-Line ReinforcementBy Application:• Orthopedic Surgery • General Surgery • Neurological Surgery • Cardiovascular Surgery • Reconstructive Surgery • Gynecological Surgery • Urological Surgery • Other surgeries (Thoracic surgeries & more)By Source/Origin• Biologic• Synthetic / Semi-syntheticBy End-user:• Hospitals • Ambulatory Surgical Centers • Clinics • Others.